CNS Drug Development: Same As It Ever Was

Summary

• Sage Therapeutics has been working in the area of steroid-derived compounds that affect CNS receptor signaling.
• A pivotal trial failed to show benefit, and they had several other clinical failures as well.
• They have a clinical trial readout in Huntington's disease later this fall, and man, that's a tough place to make your stand.

Ca-ssis/iStock via Getty Images

I've written a few times over the years about Sage Therapeutics (NASDAQ:SAGE), because they've been trying some interesting ideas in the antidepressant field, which is a very, very hard place to make headway.

It's been